表紙
市場調査レポート

Grunenthal GmbH - 製品パイプラインレビュー

Grunenthal GmbH - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 219819
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Grunenthal GmbH - 製品パイプラインレビュー Grunenthal GmbH - Product Pipeline Review - 2015
出版日: 2015年06月17日 ページ情報: 英文 47 Pages
概要

Grunenthal GmbH は研究に主眼を置く、世界規模の製薬会社です。特に疼痛治療と、実証済みの有効成分を革新的な手法で処方することにかけて長け、疼痛治療薬を開発・製造・販売しています。

当レポートでは、Grunenthal GmbHにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Grunenthal GmbHの基本情報

Grunenthal GmbHの概要

  • 主要情報
  • 企業情報

Grunenthal GmbH:R&Dの概要

  • 主な治療範囲

Grunenthal GmbH:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Grunenthal GmbH:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Grunenthal GmbH:開発段階が不明のパイプライン製品

  • 開発段階が不明の製品/併用療法モダリティ

Grunenthal GmbH:薬剤プロファイル

  • cebranopadol
  • tapentadol hydrochloride
  • tapentadol hydrochloride ER
  • GRT-6010
  • GRT-6011
  • Small Molecule 1 for Pain
  • Small Molecule 2 for Pain
  • GRTTA-2210
  • RO-656570
  • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
  • Small Molecule-3 for Pain
  • Small Molecule for Pain
  • (oxycodone + naloxone)
  • GRT-6006

Grunenthal GmbH:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Grunenthal GmbH:最近のパイプライン動向

Grunenthal GmbH:休止中のプロジェクト

Grunenthal GmbH:企業発表

Grunenthal GmbH:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07172CDB

Summary

Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2015', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grunenthal GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Grunenthal GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Grunenthal GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Grunenthal GmbH's pipeline products

Reasons to buy

  • Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Grunenthal GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Grunenthal GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Grunenthal GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grunenthal GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Grunenthal GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Grunenthal GmbH Snapshot
    • Grunenthal GmbH Overview
    • Key Information
    • Key Facts
  • Grunenthal GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Grunenthal GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Grunenthal GmbH - Pipeline Products Glance
    • Grunenthal GmbH - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Grunenthal GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Grunenthal GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Grunenthal GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Grunenthal GmbH - Drug Profiles
    • cebranopadol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tapentadol hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRTTA-2210
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RO-656570
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule-3 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lexanopadol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target KCNQ and TSPO for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Grunenthal GmbH - Pipeline Analysis
    • Grunenthal GmbH - Pipeline Products by Target
    • Grunenthal GmbH - Pipeline Products by Route of Administration
    • Grunenthal GmbH - Pipeline Products by Molecule Type
    • Grunenthal GmbH - Pipeline Products by Mechanism of Action
  • Grunenthal GmbH - Recent Pipeline Updates
  • Grunenthal GmbH - Dormant Projects
  • Grunenthal GmbH - Company Statement
  • Grunenthal GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Grunenthal GmbH, Key Information
  • Grunenthal GmbH, Key Facts
  • Grunenthal GmbH - Pipeline by Indication, 2015
  • Grunenthal GmbH - Pipeline by Stage of Development, 2015
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2015
  • Grunenthal GmbH - Partnered Products in Pipeline, 2015
  • Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2015
  • Grunenthal GmbH - Phase III, 2015
  • Grunenthal GmbH - Phase II, 2015
  • Grunenthal GmbH - Phase I, 2015
  • Grunenthal GmbH - Preclinical, 2015
  • Grunenthal GmbH - Discovery, 2015
  • Grunenthal GmbH - Unknown, 2015
  • Grunenthal GmbH - Pipeline by Target, 2015
  • Grunenthal GmbH - Pipeline by Route of Administration, 2015
  • Grunenthal GmbH - Pipeline by Molecule Type, 2015
  • Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2015
  • Grunenthal GmbH - Recent Pipeline Updates, 2015
  • Grunenthal GmbH - Dormant Developmental Projects,2015
  • Grunenthal GmbH, Other Locations
  • Grunenthal GmbH, Subsidiaries

List of Figures

  • Grunenthal GmbH - Pipeline by Top 10 Indication, 2015
  • Grunenthal GmbH - Pipeline by Stage of Development, 2015
  • Grunenthal GmbH - Monotherapy Products in Pipeline, 2015
  • Grunenthal GmbH - Pipeline by Top 10 Target, 2015
  • Grunenthal GmbH - Pipeline by Top 10 Route of Administration, 2015
  • Grunenthal GmbH - Pipeline by Top 10 Molecule Type, 2015
  • Grunenthal GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top